⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

August 3, 2026Annals of Internal Medicine

In older adults, mRNA-1010 vs. a licensed standard-dose influenza vaccine reduced influenza A- or B-related ILI at a median 181 d

V. L. CHEN Aaron E. Glatt

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate the effectiveness of the mRNA-1010 vaccine compared to a standard influenza vaccine in preventing influenza-related illness.
Study involving older adults
Comparison of mRNA-1010 to licensed standard-dose influenza vaccine
Follow-up duration median of 181 days
mRNA-1010 reduced influenza A- or B-related illness compared to the standard-dose vaccine.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Compares influenza A- and B-related illness in older adults, suggesting mRNA-1010 may offer benefits.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

CHEN et al. (2026) studied this question.

synapsesocial.com/papers/6a743730764cddc9499d45f6 https://doi.org/10.7326/annals-26-02527-jc

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1229. mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults Aged ≥50 YearsBlinded Clinical Trial · 2026 · 4 citations
2In healthy adults, a modified RNA vs. inactivated influenza vaccine reduced laboratory-confirmed influenza-like illness at ≥14 dHuman Clinical Trial · 2026
3Indirect comparison of mRNA-1010 versus enhanced influenza vaccines in adults aged 65 years and older during the 2024-2025 US influenza seasonHuman Clinical Trial · 2026 · 1 citations
4Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial2024 · 57 citations
5Optimized seasonal influenza mRNA vaccine compositions demonstrate safety and enhanced immunogenicity in a phase 2 studyEarly-Phase Clinical Trial · 2026 · 5 citations
6Enhanced Influenza Vaccines in Older Adults: A Systematic Review of High-Dose, MF59-Adjuvanted, and mRNA-Based VaccinesSystematic Review · 2026
7mRNA-1010 and the Future of Seasonal Influenza Prevention: Towards Next-Generation Respiratory VaccinationLate-Phase Clinical Trial · 2026 · 2 citations
8Clinical Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsMeta-Analysis · 2026
9Review: Antipsychotic drugs improve symptoms, with different levels of side effects, in schizophreniaAnnals of Internal Medicine · 2013
10MeaslesAnnals of Internal Medicine · 2026

More from Annals of Internal Medicine

More from Icahn School of Medicine at Mount Sinai